Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo.

导出 OA

翻译打印收藏纠错

作者： Alexandra,Schäfer ^[1] ; Frauke,Muecksch ^[2] ; Julio C C,Lorenzi ^[3] ; Sarah R,Leist ^[1] ; Melissa,Cipolla ^[3] ; Stylianos,Bournazos ^[4] ; Fabian,Schmidt ^[2] ; Rachel M,Maison ^[5] ; Anna,Gazumyan ^[3] ; David R,Martinez ^[1] ; Ralph S,Baric ^[1] ; Davide F,Robbiani ^[6] ; Theodora,Hatziioannou ^[3] ; Jeffrey V,Ravetch ^[7] ; Paul D,Bieniasz ^[2] ; Richard A,Bowen ^[4] ; Michel C,Nussenzweig ^[2] ; Timothy P,Sheahan ^[8]

作者单位： Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC. ^[1] Laboratory of Retrovirology, The Rockefeller University, New York, NY. ^[2] Laboratory of Molecular Immunology, The Rockefeller University, New York, NY. ^[3] Laboratory of Molecular Genetics and Immunology, The Rockefeller University, New York, NY. ^[4] Laboratory of Animal Reproduction and Biotechnology, Colorado State University, Fort Collins, CO. ^[5] Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC. ^[6] Institute for Research in Biomedicine, Università della Svizzera italiana, Bellinzona, Switzerland. ^[7] Howard Hughes Medical Institute, The Rockefeller University, New York, NY. ^[8]